BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pérez-de-lis M, Retamozo S, Flores-chávez A, Kostov B, Perez-alvarez R, Brito-zerón P, Ramos-casals M. Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety 2017;16:1255-71. [DOI: 10.1080/14740338.2017.1372421] [Cited by in Crossref: 64] [Cited by in F6Publishing: 48] [Article Influence: 12.8] [Reference Citation Analysis]
Number Citing Articles
1 Lee JI, Park KS, Cho IH. Panax ginseng: a candidate herbal medicine for autoimmune disease. J Ginseng Res 2019;43:342-8. [PMID: 31308804 DOI: 10.1016/j.jgr.2018.10.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
2 Noble GP, Lancaster E. Anti-NMDAR encephalitis in a patient with Crohn disease receiving adalimumab. Neurol Neuroimmunol Neuroinflamm 2018;5:e476. [PMID: 29988714 DOI: 10.1212/NXI.0000000000000476] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Avasarala J, Guduru Z, McLouth CJ, Wilburn A, Talbert J, Sutton P, Sokola BS. Use of anti-TNF-α therapy in Crohn's disease is associated with increased incidence of multiple sclerosis. Mult Scler Relat Disord 2021;51:102942. [PMID: 33933908 DOI: 10.1016/j.msard.2021.102942] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chighizola CB, Meroni PL. Thrombosis and Anti-phospholipid Syndrome: a 5-Year Update on Treatment. Curr Rheumatol Rep 2018;20:44. [PMID: 29850957 DOI: 10.1007/s11926-018-0741-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
5 Hutto SK, Rice DR, Mateen FJ. CNS demyelination with TNFα inhibitor exposure: A retrospective cohort study. J Neuroimmunol 2021;356:577587. [PMID: 33945946 DOI: 10.1016/j.jneuroim.2021.577587] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Yang M, Liu W, Deng Q, Liang Z, Wang Q. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27510. [PMID: 34678884 DOI: 10.1097/MD.0000000000027510] [Reference Citation Analysis]
7 Verspohl SH, Schulze-Koops H, Heine A, Schäfer VS. [Prevalence and treatment of rheumatological adverse events due to immune checkpoint inhibitor therapy]. Z Rheumatol 2020;79:797-808. [PMID: 32926217 DOI: 10.1007/s00393-020-00873-5] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Mauro VP. Codon Optimization in the Production of Recombinant Biotherapeutics: Potential Risks and Considerations. BioDrugs 2018;32:69-81. [PMID: 29392566 DOI: 10.1007/s40259-018-0261-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
9 Macaluso FS, Sapienza C, Ventimiglia M, Renna S, Cottone M, Orlando A. Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort. Scand J Gastroenterol 2019;54:1102-6. [PMID: 31491360 DOI: 10.1080/00365521.2019.1663260] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
10 Ramos-Casals M, Brito-Zerón P, Mariette X. Systemic and organ-specific immune-related manifestations of COVID-19. Nat Rev Rheumatol 2021;17:315-32. [PMID: 33903743 DOI: 10.1038/s41584-021-00608-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
11 Talbot S, MacLaren V, Lafferty H. Sclerosing cholangitis in a patient treated with nivolumab. BMJ Case Rep 2021;14:e241700. [PMID: 34049893 DOI: 10.1136/bcr-2021-241700] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Mormile I, Granata F, Punziano A, de Paulis A, Rossi FW. Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It? Biomedicines 2021;9:132. [PMID: 33535377 DOI: 10.3390/biomedicines9020132] [Reference Citation Analysis]
13 Tournoy KG, Thomeer M, Germonpré P, Derijcke S, De Pauw R, Galdermans D, Govaert K, Govaerts E, Schildermans R, Declercq I, De Brucker N, Pat K, Van Herreweghe R, Van Zandweghe L, Vanmaele L, Van Damme V, Marien H, De Craene S, Fabry I, Alexander P, Vercauter P, Demedts I. Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals. Lung Cancer 2018;115:49-55. [DOI: 10.1016/j.lungcan.2017.11.008] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
14 Rimkus CM, Schoeps VA, Boaventura M, Godoy LF, Apostolos-Pereira SL, Calich AL, Callegaro D, Lucato LT, Rovira A, Sastre-Garriga J, Leite CDC. Drug-related demyelinating syndromes: understanding risk factors, pathophysiological mechanisms and magnetic resonance imaging findings. Mult Scler Relat Disord 2021;55:103146. [PMID: 34332456 DOI: 10.1016/j.msard.2021.103146] [Reference Citation Analysis]
15 Derle E, Benli S. Ipilimumab treatment associated with myasthenic crises and unfavorable disease course. Neurol Sci 2018;39:1773-4. [DOI: 10.1007/s10072-018-3471-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Frazier KS. Kidney Effects by Alternative Classes of Medicines in Patients and Relationship to Effects in Nonclinical Toxicity Studies. Toxicol Pathol 2022;:1926233221100414. [PMID: 35608030 DOI: 10.1177/01926233221100414] [Reference Citation Analysis]
17 Taylor TRP, Galloway J, Davies R, Hyrich K, Dobson R. Demyelinating Events Following Initiation of Anti-TNFα Therapy in the British Society for Rheumatology Biologics Registry in Rheumatoid Arthritis. Neurol Neuroimmunol Neuroinflamm 2021;8:e992. [PMID: 33863839 DOI: 10.1212/NXI.0000000000000992] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Kunchok A, Aksamit AJ Jr, Davis JM 3rd, Kantarci OH, Keegan BM, Pittock SJ, Weinshenker BG, McKeon A. Association Between Tumor Necrosis Factor Inhibitor Exposure and Inflammatory Central Nervous System Events. JAMA Neurol 2020;77:937-46. [PMID: 32421186 DOI: 10.1001/jamaneurol.2020.1162] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
19 Triggianese P, Novelli L, Galdiero MR, Chimenti MS, Conigliaro P, Perricone R, Perricone C, Gerli R. Immune checkpoint inhibitors-induced autoimmunity: The impact of gender. Autoimmun Rev 2020;19:102590. [PMID: 32561463 DOI: 10.1016/j.autrev.2020.102590] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
20 Karampitsakos T, Vraka A, Bouros D, Liossis SN, Tzouvelekis A. Biologic Treatments in Interstitial Lung Diseases. Front Med (Lausanne) 2019;6:41. [PMID: 30931306 DOI: 10.3389/fmed.2019.00041] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
21 Lucchini M, Giuffrè GM, Nociti V, Bianco A, De Fino C, Losavio FA, Presicce G, Calabresi P, Mirabella M. Defining the disease course of TNFα blockers-associated Multiple Sclerosis. J Neuroimmunol 2021;353:577525. [PMID: 33647875 DOI: 10.1016/j.jneuroim.2021.577525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kowalski T, Mack HG. Ocular complications of tumour necrosis factor alpha inhibitors. Clin Exp Optom 2020;103:148-54. [PMID: 31077451 DOI: 10.1111/cxo.12904] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
23 Vaglio A, Grayson PC, Fenaroli P, Gianfreda D, Boccaletti V, Ghiggeri GM, Moroni G. Drug-induced lupus: Traditional and new concepts. Autoimmun Rev. 2018;17:912-918. [PMID: 30005854 DOI: 10.1016/j.autrev.2018.03.016] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 8.8] [Reference Citation Analysis]
24 Tzanetakou V, Stergianou D, Giamarellos-Bourboulis EJ. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. Expert Opin Drug Saf 2020;19:381-93. [PMID: 32098513 DOI: 10.1080/14740338.2020.1734560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
25 Leipe J, Mariette X. Management of rheumatic complications of ICI therapy: a rheumatology viewpoint. Rheumatology (Oxford) 2019;58:vii49-58. [PMID: 31816078 DOI: 10.1093/rheumatology/kez360] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
26 Bejan-Angoulvant T, Alexandre J. [Mechanism of action and adverse effects of monoclonal antibodies]. Med Sci (Paris) 2019;35:1114-20. [PMID: 31903925 DOI: 10.1051/medsci/2019208] [Reference Citation Analysis]
27 Chessa E, Piga M, Floris A, Congia M, Cangemi I, Mathieu A, Cauli A. Biologics and Targeted Synthetic Drugs Can Induce Immune-Mediated Glomerular Disorders in Patients with Rheumatic Diseases: An Updated Systematic Literature Review. BioDrugs 2021;35:175-86. [PMID: 33595833 DOI: 10.1007/s40259-021-00467-w] [Reference Citation Analysis]
28 Alijotas-Reig J, Esteve-Valverde E, Llurba E, Gris JM. Treatment of refractory poor aPL-related obstetric outcomes with TNF-alpha blockers: Maternal-fetal outcomes in a series of 18 cases. Semin Arthritis Rheum 2019;49:314-8. [PMID: 30824278 DOI: 10.1016/j.semarthrit.2019.02.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
29 Melissaropoulos K, Klavdianou K, Filippopoulou A, Kalofonou F, Kalofonos H, Daoussis D. Rheumatic Manifestations in Patients Treated with Immune Checkpoint Inhibitors. Int J Mol Sci 2020;21:E3389. [PMID: 32403289 DOI: 10.3390/ijms21093389] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
30 Uchida M, Kamoi K, Ando N, Wei C, Karube H, Ohno-Matsui K. Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious Conditions in vitro. Front Microbiol 2019;10:2148. [PMID: 31620105 DOI: 10.3389/fmicb.2019.02148] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
31 Pollard KM, Cauvi DM, Mayeux JM, Toomey CB, Peiss AK, Hultman P, Kono DH. Mechanisms of Environment-Induced Autoimmunity. Annu Rev Pharmacol Toxicol 2021;61:135-57. [PMID: 32857688 DOI: 10.1146/annurev-pharmtox-031320-111453] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Omran NE, Noorwali AA. Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report. Int J Gen Med 2018;11:151-4. [PMID: 29692623 DOI: 10.2147/IJGM.S154835] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Wroński J, Fiedor P. The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought? J Clin Pharmacol 2019;59:445-62. [PMID: 30476367 DOI: 10.1002/jcph.1348] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
34 Loebenstein M, Schulberg JD. Anti-TNF Rechallenge After Infliximab Induced Lupus in Crohn’s Disease. Gastroenterology 2020;158:2069-71. [DOI: 10.1053/j.gastro.2020.01.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Mejia-Vilet JM, Parikh SV, Song H, Fadda P, Shapiro JP, Ayoub I, Yu L, Zhang J, Uribe-Uribe N, Rovin BH. Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare. Nephrol Dial Transplant 2019;34:1197-206. [PMID: 29800348 DOI: 10.1093/ndt/gfy125] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
36 Conrad K, Shoenfeld Y, Fritzler MJ. Precision health: A pragmatic approach to understanding and addressing key factors in autoimmune diseases. Autoimmun Rev 2020;19:102508. [PMID: 32173518 DOI: 10.1016/j.autrev.2020.102508] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
37 Shoenfeld Y, Ehrenfeld M, Perry O. The kaleidoscope of autoimmunity – From genes to microbiome. Clinical Immunology 2019;199:1-4. [DOI: 10.1016/j.clim.2018.12.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
38 Murphy MJ, Cohen JM, Vesely MD, Damsky W. Paradoxical eruptions to targeted therapies in dermatology: A systematic review and analysis. J Am Acad Dermatol 2020:S0190-9622(20)33154-6. [PMID: 33307146 DOI: 10.1016/j.jaad.2020.12.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
39 Verspohl SH, Holderried T, Behning C, Brossart P, Schäfer VS. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis 2021;13:1759720X211006963. [PMID: 33912248 DOI: 10.1177/1759720X211006963] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Benfaremo D, Manfredi L, Luchetti MM, Gabrielli A. Musculoskeletal and Rheumatic Diseases Induced by Immune Checkpoint Inhibitors: A Review of the Literature. Curr Drug Saf 2018;13:150-64. [PMID: 29745339 DOI: 10.2174/1574886313666180508122332] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
41 Kutlu Ö, Çetinkaya P, Şahin T, Ekşioğlu HM. The Effect of Biological Agents on Antinuclear Antibody Status in Patients with Psoriasis: A Single-Center Study. Indian Dermatol Online J 2020;11:904-9. [PMID: 33344337 DOI: 10.4103/idoj.IDOJ_164_20] [Reference Citation Analysis]
42 Obi ON, Lower EE, Baughman RP. Biologic and advanced immunomodulating therapeutic options for sarcoidosis: a clinical update. Expert Rev Clin Pharmacol 2021;14:179-210. [PMID: 33487042 DOI: 10.1080/17512433.2021.1878024] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Pagan A, Arroyo-Martinez YM, Tandon A, Bertran-Rodriguez C, Gill J. Immune Checkpoint Inhibitor-Induced Acute Pancreatitis and Colitis. Cureus 2020;12:e8613. [PMID: 32550093 DOI: 10.7759/cureus.8613] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
44 Thiriveedi M, Steuber TD, Hasan M, Baggett A. Infliximab-Induced Lupus Causing Pericarditis: a Case Report and Review of the Literature. J Gen Intern Med 2021;36:2134-8. [PMID: 33855671 DOI: 10.1007/s11606-021-06781-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Tolu S, Rezvani A, Hindioglu N, Calkin Korkmaz M. Etanercept-induced Crohn’s disease in ankylosing spondylitis: a case report and review of the literature. Rheumatol Int 2018;38:2157-62. [DOI: 10.1007/s00296-018-4165-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
46 Thanarajasingam U, Abdel-Wahab N. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. Rheum Dis Clin North Am 2020;46:587-603. [PMID: 32631606 DOI: 10.1016/j.rdc.2020.04.003] [Reference Citation Analysis]
47 Steeland S, Libert C, Vandenbroucke RE. A New Venue of TNF Targeting. Int J Mol Sci 2018;19:E1442. [PMID: 29751683 DOI: 10.3390/ijms19051442] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 13.0] [Reference Citation Analysis]
48 Su X, Cheng Y, Chang D. Lipid-lowering therapy: Guidelines to precision medicine. Clin Chim Acta 2021;514:66-73. [PMID: 33359059 DOI: 10.1016/j.cca.2020.12.019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
49 Hirschmann S, Fischer S, Klenske E, Dechant K, Distler JHW, Treutlein C, Neurath MF, Atreya R. Case report of severe constrictive perimyocarditis and ischemic hepatitis in a Crohn's disease patient upon infliximab-induced lupus-like syndrome. Therap Adv Gastroenterol 2021;14:17562848211044033. [PMID: 34616488 DOI: 10.1177/17562848211044033] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Rad F, Ghorbani M, Mohammadi Roushandeh A, Habibi Roudkenar M. Mesenchymal stem cell-based therapy for autoimmune diseases: emerging roles of extracellular vesicles. Mol Biol Rep. 2019;46:1533-1549. [PMID: 30623280 DOI: 10.1007/s11033-019-04588-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 10.7] [Reference Citation Analysis]
51 Gaboriau L, Davion JB, Combret S, Lebrun-Vignes B, Rocher F, Rouby F, Renaud F, Morell-Dubois S, Gautier S. Adalimumab and myositis: A case report and review of the French and international Pharmacovigilance Databases. Neuromuscul Disord 2020;30:915-20. [PMID: 33071068 DOI: 10.1016/j.nmd.2020.09.026] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
52 Demarez B, Amatore F, Lagarde S, Bruder N, Grob J, Richard M. Anti‐ N ‐methyl‐ D ‐aspartate receptor encephalitis during treatment with adalimumab for psoriasis. J Eur Acad Dermatol Venereol 2020;34. [DOI: 10.1111/jdv.16456] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Chighizola CB, Andreoli L, Gerosa M, Tincani A, Ruffatti A, Meroni PL. The treatment of anti-phospholipid syndrome: A comprehensive clinical approach. J Autoimmun 2018;90:1-27. [PMID: 29449131 DOI: 10.1016/j.jaut.2018.02.003] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 9.3] [Reference Citation Analysis]
54 Frazier KS, Obert LA. Drug-induced Glomerulonephritis: The Spectre of Biotherapeutic and Antisense Oligonucleotide Immune Activation in the Kidney. Toxicol Pathol 2018;46:904-17. [PMID: 30089413 DOI: 10.1177/0192623318789399] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
55 Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology (Oxford) 2019;58:vii40-8. [PMID: 31816084 DOI: 10.1093/rheumatology/kez297] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 9.5] [Reference Citation Analysis]